Fig. 1From: Influence of Mitroflow bioprosthesis structural valve deterioration on cardiac morbidityEnrolment of patients who had received Mitroflow bioprosthesis and died within the study period (February 2001 – April 2014). Group 1: Cardiovascular death due to SVD; Group 2: Cardiovascular death with no SVD; Group 3: Non-cardiovascular death without SVDBack to article page